FDA Approves Tibsovo Combination for Older Patients with Leukemia

May 26th 2022

Tibsovo is the first therapy targeting cancer metabolism for patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

FDA Issues Second CRL for Poxvirus Treatment

May 26th 2022

Deficiencies at the contract manufacturing company are, for the second time, holding up approval of VP-102 to treat molluscum contagiosum, a mild skin infection.

FDA Accepts BLA for Hemophilia B Gene Therapy

May 25th 2022

If approved, etranacogene dezaparvovec would be the first gene therapy for patients with hemophilia B. An FDA decision is expected in November 2022.

Shining Light on the Barriers Payers Place on Medications

May 25th 2022

Molly Beinfeld, senior research lead, evidence synthesis at the Institute for Clinical and Economic Review, talks about the organization’s research assessing payer coverage policies of prescription drugs.

Teva Recalls One Lot of Anagrelide

May 25th 2022

The impacted lot failed a dissolution test, meaning it was taking longer to dissolve once ingested. This can result in less anagrelide available in the body, possibly leading to clotting or bleeding events such as a heart attack or stroke.